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includes diagnosis and subsequent treatment. Whilst there are differences in the
results between countries due to coding practices and population, the results are
consistent over time and suggest a role for diagnostic interventions which can
speed up diagnosis, thus ensuring more appropriate patient management at an
earlier stage.
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OBJECTIVES: Atrial fibrillation (AF) is an arrhythmia that progressively worsens
and is characterized by uncoordinated atrial activation involving a rapid and irreg-
ular heart rate (Fuster et al., 2006). AF patients are likely to have concomitant
congestive heart failure (CHF) and stroke (Lee et al., 2008). The prevalence of AF in
adults 65 years is 5-6%, increasing with age (Go et al., 2001). The purpose of this
study was to estimate the economic burden of AF in selected developed countries
based on prevalence and direct health care costs.METHODS:The economic burden
of AF in Belgium, Japan, The Netherlands, and Spain was modeled based on prev-
alence rates identified via a literature search. Annual probabilities of receiving
health care treatment and associated costs for AF, stroke and CHF, and related
disability costs were included in the model. If cost data were unavailable, the costs
were imputed based on the ratio of annual per capita health expenditures between
the US and the country of interest. Cost estimates were calculated in 2011 euros.
RESULTS: The prevalence of AF in adults aged 65 in the countries studied was:
59,600 in Belgium; 83,400 in the Netherlands; 182,000 in Spain; and 593,400 in Japan.
The estimated annual economic burden of AF was: EUR 181.2 in Belgium; 256.6 in
the Netherlands; 333.5 in Spain; and 1,722.5 in Japan (in millions). CONCLUSIONS:
The economic burden of AF in developed countries is substantial, and is expected
to grow as the population ages. Early detection and appropriate management of AF
may help reduce this economic burden.
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OBJECTIVES: To evaluate the burden of SSI (surgery site infection) in common
surgeries in Korea. The considered surgeries: gastrointestinal surgery, Coronary
Artery Bypass Grafting (CABG) and orthopaedic surgery represent the procedures
with high, medium and low SSI risk. METHODS: The analysis was conducted from
the hospital perspective. Costs were evaluated on the basis of Health Insurance
Review Agency (HIRA) data. Risk of SSI and the influence of SSI on hospital length
of stay (LOS) were calculated according to studies from a review Lee 2011. The
influence of prolonged hospitalization on expenses was obtained with an assump-
tion that the costs are evenly distributed during the stay. RESULTS: The risk of SSI
depends on surgery type. Among the procedures considered, the highest SSI rate –
5% was related to gastric surgery and the lowest SSI rate – 1% to knee replacement.
LOS in case of SSI is prolonged for about 60%. According to current data on hospi-
talization cost from HIRA, the influence of SSI on providers’ budget could be sub-
stantial. The estimated increase in hospitalization cost induced by SSI is about 3.9
million won (2.700 €) for gastrointestinal surgery, 4.3 million won (3.000 €) for or-
thopaedic surgery and even 10.0 million won (6.900 €) for CABG. Halving the SSI rate
would reduce the mean expenses for about 1%. CONCLUSIONS: The burden of SSI
in Korea is high as SSI implies the significant prolongation of LOS. The detailed
analysis should then be carried out in order to define the possible ways of mini-
mizing the infection risk. The possible range of relatively non expensive risk-re-
ducing interventions which may imply the substantial reduction of SSI rate include
the use of antimicrobial sutures, antibiotics prophylactics, a safety checklist and
other. The increased cost of SSI prevention would be probably broadly offset by the
decreased costs of hospital stay.
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OBJECTIVES: To assess the cost of using continuous subcutaneous insulin infusion
(CSII) to treat children with diabetes and to compare it with the changes in HbA (1c)
and BMI. The study was performed from the point of view of the health insurance
fund and patients. METHODS: A combined retrospective and prospective analysis
of the patients’ records after the introduction of CSII was performed. Cost of CSII,
blood glucose monitoring system and strips was calculated. The primary outcome
observed was the variation in HbA(1c) and the secondary was the BMI change.
RESULTS: Subcutaneous insulin infusion (CSII) systems are of a limited usage be-
cause they are not reimbursed by the health insurance fund in the country. The
university pediatric clinic is introducing them on the request of the parents and
only 30 children apply such. 11 children with diabetes type 1 during the period
1999–2011 were observed (mean age 10 years, mean duration of the disease is 7
years, average usage of CSII - 3 years). The CSII price is 3896 Euro and compared to
the duration of usage it costs 1292 euro per patient per year. The blood glucose
monitoring system costs 20 Euro and for the duration of the disease - 4.96 Euro per
patient per year. The test stripes costs 533 Euro/ year (1100 stripes per year) and
their average cost according to the duration of the disease is 3779.45 Euro since
diagnosis. Thus the total yearly cost weighed with the duration of the disease is
1850 Euro (30% reimbursed). The average improvement of HbA (1c) after the CSII
introduction is 1.72 and the average BMI was 37.03. CONCLUSIONS: Improvements
in glycemic control associated with CSII led to reduced HbA(1c) that can guarantee
good diabetes management, but its control over BMI in growing children is still
unclear.
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OBJECTIVES: The frequency of newly diagnosed thyroid nodule is increasing, prob-
ably because of the widespread use of ultrasonography in Korea. However, there
are few researches about the incidence of thyroid cancer in patient with thyroid
nodules using national representative data. This study is performed to investigate
the incidence of thyroid cancer and medical costs among patients who were newly
diagnosed as thyroid nodule in South Korea. METHODS: We analyzed national
health claim database including all hospital records covering almost every popu-
lation by national health insurance system. We selected patients aged 20-120 years
old with thyroid nodules using ICD-10 codes of D34*, E041, E042 in 2008. We ex-
cluded all patients who were previously reported to have a thyroid nodule or any
type of cancer including thyroid cancer between 2006 and 2007. We conducted a
follow-up survey of the selected subjects on the national health claim database at
least for 2 years after diagnosis. RESULTS: We identified 283,844 eligible patients
with thyroid nodules. Their mean age 4813.2, and 234,388 (82.58%) subjects were
female. During median follow-up of 2.4 years, 21,538 (7.6%) Lower age, history of
thyroid disease or diabetes was associated with the risk of thyroid cancer. Mean
direct medical cost per patient paid by national insurer or shared by patient related
with newly diagnosis of thyroid nodules were about 475 Euros during follow up.
The medical cost of thyroid nodules subjects was 271 Euros, and it was especially
higher in patients with thyroidectomy (1378 Euros). CONCLUSIONS: In Korea, the
incidence of thyroid cancer was relatively higher, while the medical cost was much
lower than other countries, suggesting that careful follow-up for thyroid nodules
requited in Korea. Further study is needed to identify the risk factors of thyroid
cancer in patients with thyroid nodules.
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OBJECTIVES: Cervical degenerative disc disorders are increasingly common in
adults. Patients refractory to conservative therapy require surgery for relief of pain.
This micro-costing study sought to compare actual costs of index hospitalization
versus DRG revenue for cervical disc arthroplasty (CDA) in order to explore the
financial profit or loss of this emerging intervention for German hospitals.
METHODS:As published data is scarce, detailed in-hospital resource utilization for
1-level or 2-level CDA was mainly based on information supplied by three experi-
enced neurosurgeons from private and public German hospitals. Where available,
these estimates were compared and calibrated with existing data. Unit costs col-
lected from hospital accounting departments and information from German refer-
ence cost databases and the published literature were subsequently assigned to the
resource use items for the calculation of actual hospital costs associated with CDA.
RESULTS: Average total per-patient hospital costs were estimated at €5,930 for
1-level and €8,768 for 2-level arthroplasty. Most important cost drivers were the
costs of materials & disposables required for the intervention (relative contribution
to total hospital costs for 1-level CDA: 44%, for 2-level CDA: 58%), followed by
hospital ward costs (27%, 18%), use of operating and recovery room (15%, 13%),
OR-team (8%, 7%), and diagnostic examinations (6%, 4%). With current G-DRG pay-
ments for mono-segmental CDA (€6,620) and bi-segmental CDA (€9,815), German
hospitals can achieve average earnings of €690 (1-level CDA) and of €1,047 (2-level
CDA) when performing this emerging disc replacement technique.CONCLUSIONS:
Our costing study indicates that 1- or 2-level CDA represents a feasible and finan-
cially sustainable surgical therapy for German hospitals. First evidence from the
literature also tends to show that CDA is associated with additional long-term
benefits in terms of reduced rates of disc reoperations compared to conventional
anterior cervical discectomy and fusion.
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OBJECTIVES: To estimate the costs and benefits of diagnosis strategies using DNA
testing for mucinous pancreatic cysts (MPCs). METHODS: A decision tree was con-
structed that compared three diagnostic strategies for pancreatic cysts: 1) endo-
scopic ultrasound-guided fine needle aspiration (EUS-FNA) with cyst fluid testing
for carcinoembryonic antigen (CEA); 2) strategy 1DNA testing if insufficient fluid
for a CEA; 3) strategy 2DNA testing if the CEA is indeterminate. Probabilities of
insufficient fluid, positive, negative, and, indeterminate CEA results, and positive
DNA results given insufficient fluid or indeterminate results were calculated from
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